Glenmark Pharmaceuticals's US arm has launched a generic version of Clindamycin Phosphate foam, an antibiotic acne treatment.

Glenmark Pharmaceuticals Ltd on Wednesday said its US arm has launched the generic version of Clindamycin Phosphate foam, an.

Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the launch1 of Clindamycin Phosphate Foam, 1%. Glenmark's Clindamycin Phosphate Foam, 1% is bioequivalent and therapeutically equivalent to the ...

According to IQVIA sales data for the 12-month period ending December 2024, the Evoclin Foam, 1% market achieved annual sales of approximately $5.8 million ...

Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the launch of clindamycin phosphate foam, 1%. Glenmark’s clindamycin phosphate foam, 1% is bioequivalent and therapeutically equivalent to the ...

This new product is bioequivalent and therapeutically equivalent to the reference-listed drug, Evoclin Foam, 1%, manufactured ...

Glenmark Pharmaceuticals has announced the launch of Clindamycin Phosphate Foam, which is a bioequivalent and therapeutically equivalent to the reference listed drug, Evoclin Foam of Mylan ...

Clindamycin and erythromycin inhibit protein synthesis by irreversibly binding to the ribosomal 50S subunit of P. acnes (Physician's Desk Reference, 2001). Whereas erythromycin is bactericidal ...

Torrey Pines Investment, a specialty life-science investment company based in San Diego, CA, and Oost NL, a regional development agency supporting innovation-driven companies, announced the pre-seed ...

For example, if the control patient has a history of a cutaneous adverse drug reaction after ingesting acetaminophen and clindamycin and this reaction is confirmed either by skin tests or repeat ...